Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial ResultsGlobeNewsWire • 08/08/22
Corvus Pharmaceuticals Appoints Dr. James Rosenbaum Senior Vice President of ResearchGlobeNewsWire • 07/21/22
Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/11/22
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial ResultsGlobeNewsWire • 03/10/22
Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022GlobeNewsWire • 03/03/22
Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Initiated Phase 1/1b Clinical Trial of ITK Inhibitor CPI-818 in ChinaGlobeNewsWire • 01/13/22
New Preclinical Data Highlights Potential for CPI-818 (ITK Inhibitor) as a Therapy for Acute Graft Versus Host Disease in Patients Receiving Bone Marrow TransplantationGlobeNewsWire • 12/13/21
5 White-Hot Stocks Trading Under $10 to Buy Now Have Great Upside Potential24/7 Wall Street • 12/04/21
Corvus Pharmaceuticals Presents Updated Data from Mupadolimab (Anti-CD73) Phase 1/1b Clinical Trial at the 2021 Society for Immunotherapy of Cancer (SITC) Annual MeetingGlobeNewsWire • 11/12/21
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2021 Financial ResultsGlobeNewsWire • 11/01/21
Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for Phase 1/1b Clinical Trial of ITK Inhibitor CPI-818 in ChinaGlobeNewsWire • 10/27/21
Angel Pharmaceuticals Announces Approval of IND Application in China for ITK Inhibitor CPI-818PRNewsWire • 10/25/21
Corvus Pharmaceuticals Provides Updates on Mupadolimab (Anti-CD73) Programs in Oncology and Infectious DiseaseGlobeNewsWire • 09/22/21
Implied Volatility Surging for Corvus Pharmaceuticals (CRVS) Stock OptionsZacks Investment Research • 09/20/21